Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
Boutagy NE, Feher A, Pfau D, Liu Z, Guerrera NM, Freeburg LA, Womack SJ, Hoenes AC, Zeiss C, Young LH, Spinale FG, Sinusas AJ. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity. JACC CardioOncology 2020, 2: 774-787. PMID: 33437965, PMCID: PMC7799406, DOI: 10.1016/j.jaccao.2020.09.007.Peer-Reviewed Original ResearchSac/ValRodent modelsControl animalsMMP activityMatrix metalloproteinasesAngiotensin receptor blocker therapyAngiotensin receptor-neprilysin inhibitionTime-matched control animalsMyocardial MMP activityReceptor blocker therapySacubitril/valsartanHeart failure patientsVentricular ejection fractionAnthracycline-induced cardiotoxicityDoxorubicin-Induced CardiotoxicityMale Wistar ratsSubgroup of animalsBlocker therapyAldosterone inhibitorsSystolic dysfunctionFailure patientsEjection fractionCardioprotective actionVentricular remodelingMyocardial infarction